Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

16.12 +0.66 (+4.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.  - SMMT
From Pomerantz LLP
Via GlobeNewswire
News headline image
Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
From Summit Therapeutics Inc.
Via Business Wire
News headline image
2 Soaring Stocks Wth More Upside Potential ↗
Via The Motley Fool
News headline image
3 No-Brainer Healthcare Stocks to Buy in June ↗
Via The Motley Fool
News headline image
Earnings Scheduled For May 1, 2025 ↗
 
Via Benzinga
News headline image
Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy? ↗
Via The Motley Fool
News headline image
Temu Parent PDD, Regeneron Pharmaceutical And Burlington Stores Are Among Top 11 Large-Cap Losers Last Week (May 26-May 30): Are The Others In Your Portfolio? ↗
11 large-cap stocks with worst performance in last week: SMMT, PDD, REGN, BAH, OKTA, DECK, CPRT, COO, TPL, HPQ, BURL. Mixed results, lowered forecasts. 
Via Benzinga
News headline image
Which stocks are experiencing notable movement on Friday? ↗
Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
Dow Edges Higher; Dell Shares Fall After Q1 Results ↗
 
Via Benzinga
Topics Stocks
News headline image
Why Summit Therapeutics Plunged Today ↗
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Top movers in Friday's session ↗
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Summit Therapeutics Stock Tumbles On Oncology Drug Trial Data, Retail Flags ‘Insane’ Valuation ↗
Summit now intends to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration seeking approval for Ivonescimab plus chemotherapy based on the results of the trial. 
Via Stocktwits
Topics Lawsuit Regulatory Compliance
News headline image
Traders are paying attention to the gapping stocks in Friday's session. ↗
Traders are paying attention to the gapping stocks in Friday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
News headline image
Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure ↗
There's a long history of anti-PD-1 and anti-VEGF drugs working to slow progression, but not improve overall survival. 
Via Investor's Business Daily
News headline image
Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint ↗
Summit Therapeutics' Phase 3 trial met the primary goal in lung cancer, showing significant PFS benefit with ivonescimab plus chemotherapy. 
Via Benzinga
News headline image
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study
From Summit Therapeutics Inc.
Via Business Wire
News headline image
3 High-Flying Stocks That Could Soar Even More ↗
Via The Motley Fool
News headline image
Treasury Yields Top 5%: These 20 Stocks Tanked In Just One Hour ↗
The selloff came as investors repriced risk across equities amid fears of persistently higher rates, sparked by soft demand at the 20-year Treasury auction. 
Via Benzinga
News headline image
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 ↗
Via The Motley Fool
Topics Economy Law Enforcement
News headline image
Got $100? 3 Top Growth Stocks to Buy That Could Double Your Money ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
News headline image
Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio? ↗
The worst performing large-cap stocks last week: ARGENX, VRTX, SMMT, MMYT, REGN, RKT, BNTX, AFRM, FNF, LLY, AUR, DASH. Any in your portfolio? 
Via Benzinga
News headline image
Can Summit Therapeutics Stock Double Your Money? ↗
Via The Motley Fool
News headline image
Duolingo, CoreWeave And DexCom Are Among Top 10 Large-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio? ↗
Top performing large-cap stocks in the last week: DUOL, CRWV, THC, CARR, SMMT, AUR, ANET, TT, DXCM, XPO. Most had positive financial results and raised guidance. 
Via Benzinga
News headline image
This Soaring Stock Just Delivered More Good News. Time to Buy? ↗
Via The Motley Fool
News headline image
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025
From Summit Therapeutics Inc.
Via Business Wire
News headline image
9 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Why Is Summit Therapeutics Stock Trading Higher On Monday? ↗
Summit Therapeutics highlights China approval of Akeso's ivonescimab for NSCLC, with enrollment ongoing for Phase 3 HARMONi-7 trial. 
Via Benzinga
News headline image
Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.